A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

doi:10.1016/j.nmni.2021.100895

Review

. 2021 Jul:42:100895.

doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

M Shabani¹, B Sadegh Ehdaei², F Fathi³, R Dowran¹

Affiliations

¹ Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
² Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
³ Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 33976895
PMCID: PMC8103737
DOI: 10.1016/j.nmni.2021.100895

Review

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

M Shabani et al. New Microbes New Infect. 2021 Jul.

. 2021 Jul:42:100895.

doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.

Authors

M Shabani¹, B Sadegh Ehdaei², F Fathi³, R Dowran¹

Affiliations

¹ Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
² Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
³ Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 33976895
PMCID: PMC8103737
DOI: 10.1016/j.nmni.2021.100895

Abstract

Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.

Keywords: COVID-19; HCV; SARS-CoV-2; daclatasvir; sofosbuvir.

PubMed Disclaimer

Cited by

Severe COVID-19: Drugs and Clinical Trials.
Ceja-Gálvez HR, Renteria-Flores FI, Nicoletti F, Hernández-Bello J, Macedo-Ojeda G, Muñoz-Valle JF. Ceja-Gálvez HR, et al. J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893. J Clin Med. 2023. PMID: 37109231 Free PMC article. Review.
UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma.
El-Shorbagy HI, Mohamed MA, El-Gindy A, Hadad GM, Belal F. El-Shorbagy HI, et al. Sci Rep. 2024 Sep 18;14(1):21758. doi: 10.1038/s41598-024-71413-3. Sci Rep. 2024. PMID: 39294224 Free PMC article.
Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses.
Awad AM, Hansen K, Del Rio D, Flores D, Barghash RF, Kakkola L, Julkunen I, Awad K. Awad AM, et al. Biomolecules. 2023 Sep 26;13(10):1452. doi: 10.3390/biom13101452. Biomolecules. 2023. PMID: 37892134 Free PMC article. Review.
Dibenzo-18-crown-6-based carbon paste sensors for the nanomolar potentiometric determination of daclatasvir dihydrochloride: An anti-HCV drug and a potential candidate for treatment of SARS-CoV-2.
Ahmed YM, Badawy SS, Abdel-Haleem FM. Ahmed YM, et al. Microchem J. 2022 Jun;177:107276. doi: 10.1016/j.microc.2022.107276. Epub 2022 Feb 10. Microchem J. 2022. PMID: 35169329 Free PMC article.
Assessment of binding interaction to salmon sperm DNA of two antiviral agents and ecofriendly nanoparticles: comprehensive spectroscopic study.
Abdel Hakiem AF, El-Sagheir AMK, Draz ME, Mohamed NA, Aboraia AS. Abdel Hakiem AF, et al. BMC Chem. 2023 Apr 19;17(1):39. doi: 10.1186/s13065-023-00952-z. BMC Chem. 2023. PMID: 37076904 Free PMC article.

See all "Cited by" articles

References

1. Masters P.S. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. - PMC - PubMed
1. Han R., Zhou J., François C., Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655. - PMC - PubMed
1. Thuluvath P., Guidinger M., Fung J., Johnson L., Rayhill S., Pelletier S. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010;10(4p2):1003–1019. - PubMed
1. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273. e1. - PMC - PubMed
1. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Masters P.S. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. - PMC - PubMed

[2] Masters P.S. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. - PMC - PubMed

[3] Han R., Zhou J., François C., Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655. - PMC - PubMed

[4] Han R., Zhou J., François C., Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655. - PMC - PubMed

[5] Thuluvath P., Guidinger M., Fung J., Johnson L., Rayhill S., Pelletier S. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010;10(4p2):1003–1019. - PubMed

[6] Thuluvath P., Guidinger M., Fung J., Johnson L., Rayhill S., Pelletier S. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010;10(4p2):1003–1019. - PubMed

[7] El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273. e1. - PMC - PubMed

[8] El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273. e1. - PMC - PubMed

[9] Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327. - PMC - PubMed

[10] Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

Affiliations

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous